| Document |
Document Title |
|
WO/2024/055023A3 |
Compositions and methods are provided that enhance CAR T-cell therapy by providing an oncolytic virus engineered to direct expression and secretion of a multivalent adapter protein. The multivalent adapter protein targets both a broadly ...
|
|
WO/2024/088712A1 |
The present invention relates to mGluR5 antagonists, or compounds 4-[5-[(rac)-1-[5-(3- Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol
-3-yl]pyridine (TT00), or a pharmaceutically acceptable salt thereof, enantiomer, isotope...
|
|
WO/2024/089683A1 |
Anticancer conjugates combining a DNA methylation agent and an anticancer drug are provided herein, as well as uses of the same in cancer treatment.
|
|
WO/2024/064721A3 |
The present disclosure is concerned with methods of treating disorders associated with overexpression of an eyes absent (EYA) protein such as, for example, vascular disease, a fibrosis-related disorder, hearing loss, and a metabolic dise...
|
|
WO/2024/087267A1 |
Provided is a chimeric antigen receptor capable of identifying and binding to TGFβRII. The chimeric antigen receptor is used in combination with a chimeric antigen receptor capable of identifying and binding to a tumor-specific antigen ...
|
|
WO/2024/091607A1 |
Provided herein are compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, provided herein are methods of treating renal cancer based on expression levels of canc...
|
|
WO/2024/091370A1 |
The present invention provides 5,6-bicyclic heteroaromatic compounds, particularly a compound of formula (I) and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula (I) in treating d...
|
|
WO/2024/089227A1 |
The present invention relates to compounds of formula I, a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment and/or prevention of conditions having an assoc...
|
|
WO/2024/088377A1 |
Disclosed are a compound as represented by general formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, X and Y are as defined in the present disclosure.
|
|
WO/2024/091957A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R100, p, ring A, L, R22', R22, R32, and R33 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound...
|
|
WO/2024/091664A1 |
This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain examples, modulators are derivatives of hexahydropental ene. In certain examples, this...
|
|
WO/2024/089013A1 |
The invention relates to a combination of a PARP inhibitor with Omomyc, a functionally equivalent variant thereof, a conjugate comprising Omomyc or said functionally equivalent variant, a polynucleotide encoding said polypeptides, a vect...
|
|
WO/2024/088967A1 |
The present invention relates to new proteins that are specific for Programmed (Cell) Death Ligand 1 (PD-L1). The PD-L1 specific proteins of the invention bind with high affinity to human and mouse PD-L1. The invention further refers to ...
|
|
WO/2024/054806A3 |
The present invention provides compositions and methods for inducing an immune response in a subject in need thereof, comprising administering to the subject an immunologically-effective amount of a live Salmonella Typhi vector, wherein ...
|
|
WO/2024/091975A1 |
This disclosure pertains to methods of treating prostate cancer in a subject, including prostate cancer comprising at least one somatic AR tumor mutation, such as metastatic prostate cancer, castrate-resistant prostate cancer, metastatic...
|
|
WO/2024/090954A1 |
The present invention relates to a composition for preventing or treating radioresistant head and neck cancer comprising an extract of Spatholobi Caulis as an active ingredient. It was confirmed that the extract of the present invention ...
|
|
WO/2024/088283A1 |
Provided in the present invention are an anti-L1CAM antibody-drug conjugate, and a preparation method therefor and the pharmaceutical use thereof. In particular, provided in the present invention are an antibody-drug conjugate (ADC) cont...
|
|
WO/2024/063740A3 |
The invention relates to hydrazide and hydrazide-hydrazone derivative molecules with antitumoral effect, bearing 1,2,4-triazole rings, which are effective on the MCF-7 breast cancer cell line and on cyclooxygenase-1 (COX-1 ), especially ...
|
|
WO/2024/088991A1 |
The present invention relates to heterocyclic compounds of formula (I) capable of activating STING (Stimulator of Interferon Genes).
|
|
WO/2024/091551A1 |
Crystalline forms and pharmaceutical compositions of a PRMTS inhibitor of formula (I), methods of making the pharmaceutical compositions of the PRMTS inhibitor of formula (I) and methods of using the PRMTS inhibitor of formula (I) or cry...
|
|
WO/2024/092009A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.
|
|
WO/2024/087423A1 |
An mRNA drug, which reduces expression in the liver after being delivered to the body, and a preparation method therefor. The preparation method comprises: establishing double 3'UTR in a target mRNA, and introducing a miR-122 binding sit...
|
|
WO/2024/064824A3 |
Genetically modified NK cells and pharmaceutical compositions and methods of use thereof for treating subjects having diseases or disorders. In some forms, the genetically modified NK cells have reduced or abrogated expression of the Cal...
|
|
WO/2024/090703A1 |
The present invention relates to an efficient natural killer (NK) cell culture method among immune cell therapies and, more particularly, to a culture method to efficiently amplify and activate immune cells after lymphocytes derived from...
|
|
WO/2024/046471A9 |
The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...
|
|
WO/2024/090488A1 |
The present invention pertains to a liquid pharmaceutical composition that contains, as an active ingredient, a complex of a radioactive isotope and an antibody. The pharmaceutical composition is characterized in that: the antibody speci...
|
|
WO/2024/061946A3 |
Provided are materials and methods for the treatment of diseases or disorders, and more particularly to the mobilization of stem cells and/or the treatment of a disease, disorder or condition involving CXCR4 receptor activity by administ...
|
|
WO/2024/089006A1 |
The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
|
|
WO/2024/092025A1 |
The present invention relates to constructs, i.e. multimeric proteins, polypeptides and polynucleotides encoding same, to methods for preparing such constructs, to pharmaceutical compositions comprising the constructs, and to the use of ...
|
|
WO/2024/088296A1 |
The present disclosure relates to a piperidinopyrimidine derivative, a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a piperidinopyrimidine derivative as represented by gener...
|
|
WO/2024/092045A1 |
Methods of synthesizing diamine platinum(II) complexes and their conjugates are disclosed.
|
|
WO/2024/087977A1 |
The present invention relates to a phenylurea compound capable of targeting SHP2, and a preparation method therefor, the use thereof and a pharmaceutical composition thereof. The compound is as represented by formula (I). The present inv...
|
|
WO/2024/059574A3 |
The disclosure concerns methods and kits of diagnosis of pancreatic cancer and monitoring disease burden in patients diagnosed with pancreatic cancer, the method comprising quantitative determination of the concentration of extracellular...
|
|
WO/2024/088829A2 |
The present invention relates to novel salts of 4-(4-methyl-piperazin-1-yl)-N-{6-[2-(4-trifluoromethyl-benzy
loxy)-ethoxy]- 1H-indazol-3-yl}-benzamide, their solvates, hydrates and polymorphs, as well as to process for their preparation,...
|
|
WO/2024/087760A1 |
Disclosed in the present invention is a method for coupling mature erythrocytes in vitro. A drug (including macromolecules such as antibodies, polypeptides and nucleotides, and chemical molecules such as chemotherapeutic drugs) is couple...
|
|
WO/2024/087265A1 |
A protein inhibitor, a reagent set, and a use thereof. The protein inhibitor is an inhibitor for inhibiting a CILK1 protein; the protein inhibitor is CILK1-C28 or CILK1-C30; the use of the protein inhibitor is to apply the protein inhibi...
|
|
WO/2024/088323A1 |
This disclosure provides compounds containing 6- (pyrimidin-4-yl) quinoline structure, the use thereof for selectively inhibiting the activity of CDK4, and pharmaceutical compositions comprising the compounds as treatment of various dise...
|
|
WO/2024/088346A1 |
Provided are anti-CCR8 (chemokine (C-C motif) receptor 8) antibodies, antigen-binding fragments, and the uses thereof.
|
|
WO/2024/092210A1 |
Provided herein are methods to treat fibrosis and/or inhibit angiogenesis.
|
|
WO/2024/090916A1 |
The present invention relates to a pharmaceutical composition for treating colon cancer, biliary tract cancer, or head and neck cancer, comprising an anti-IGSF1 antibody as an active ingredient. When the anti-IGSF1 antibody according to ...
|
|
WO/2023/183528A3 |
The present disclosure provides compositions comprising IFNE and methods of using the same to treat cancer and/or enhancing responsiveness to immune checkpoint blockade therapy in a patient in need thereof. Also disclosed herein are comp...
|
|
WO/2024/064866A3 |
Metastasis is a major cause of fatality and expense in cancer. Many metastatic patients express calcified, fibrotic, or deep-seated (lymph/Jung/brain) lesions that are not easily profiled. For such patients, decision-making regarding tre...
|
|
WO/2024/086790A1 |
The present disclosure provides 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine compounds of formula (I), which are therapeutically useful as USP1 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or...
|
|
WO/2024/082724A1 |
It relates to the combination of PIM kinase inhibitor and a KRAS inhibitor for use in treating cancer, in a subject in need thereof. Also provided are compositions or kits comprising same. Furthermore, it also relates to a PIM kinase inh...
|
|
WO/2024/083120A1 |
Disclosed in the present invention are a benzylaminoquinoline compound and a preparation method therefor. The present invention specifically relates to a compound represented by formula (II), a stereoisomer thereof and a pharmaceutically...
|
|
WO/2023/250391A9 |
Provided are compositions and methods that include binding partners that specifically bind to a peptide conjugate/MHC complex comprising a peptide conjugate that is formed by the covalent reaction of a targeted covalent inhibitor with a ...
|
|
WO/2024/086226A1 |
Methods and systems are disclosed for component deconvolution by a mixture model based on methylation information. A mixture model may be trained agnostic of labels or known component contributions. A system generates a methylation signa...
|
|
WO/2024/082408A1 |
The present invention relates to a use of a JWA polypeptide in the preparation of an anti-tumor drug co-potentiator. The amino acid sequence of the polypeptide is as shown in I or II: I: FPGSDRF-Z, and II: X-FPGSDRF-Z, the amino acid S b...
|
|
WO/2024/083166A1 |
An antibody-drug conjugate, a preparation method therefor and the use thereof in resisting tumors, which specifically relates to an anti-HER3 antibody or an antigen-binding fragment thereof, and an antibody-drug conjugate linked to the a...
|
|
WO/2024/083925A2 |
The present invention relates to novel anti-NaPi2b antibodies, antibody-drug-conjugates (ADCs) based thereon as well as to therapeutic methods and uses thereof, particularly in relation to cancer treatment.
|
